Posts Tagged ‘best med school’

Case Western Reserve think beyond the possible

February 26, 2010

“Think beyond the possible” embodies the spirit of Case Western Reserve University.
From our faculty and students to our staff and alumni, new challenges are being met with innovative thinking and discovery that go beyond the status quo.
Learn more at CWRUmedicine.org

Advertisements

The importance of Hem Onc clinical trials

February 24, 2010

Matthew Cooney, MD, discusses the importance of clinical trials in cancer treatments.
Learn more about the Division of Hematoloy Oncology :: www.CWRUmedicine.org

HemOnc approach to cancer

February 24, 2010

Matthew Cooney, MD, discusses the multidisciplinary approach to cancer treatment at the Department of Medicine at Case Western Reserve University.
Learn more about the Division of Hematoloy Oncology :: www.CWRUmedicine.org

UH System Achievement Award for Time-is-Muscle CWRUmedicine’s Cardiovascular Medicine Committee door-to-balloon time initiative

February 24, 2010

This is a multi-disciplinary team effort from EMS/Transfer Center, ED, cath lab, CICU, and Quality Center.

Median D2B reduced from 94 to 37 min with 100 per cent of pts receiving AHA/ACC recommended D2B less than 90 min.

Key Department of Medicine MDs included Madan Mohan, Rich Jospehson, Tom Lassar, Shyam Bhakta, Tom Carrigan, Marco Costa, and Dan Simon.

Learn more about Cardiovascular Medicine at CWRUmedicine

CWRUmedicine’s HemOnc researchers publish new findings that may lead to a new standard of care for patients with locally advanced cervical cancer

February 24, 2010

Published in the February 2010 issue of Clinical Cancer Research, the phase one study found that a new chemotherapy medicine, Triapine, was well tolerated in combination with standard-of-care cisplatin chemotherapy and radiation treatment in women with cervical cancer. This regimen provided both significant reduction in cancer disease and cancer control.

“This new drug, which suppresses tumor growth, shows a great deal of promise for cervical cancer patients who are at high risk for relapse and cancer-related death,” says Charles Kunos, MD, Primary Investigator of the study, Director of Gynecologic Radiation Oncology at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. “In this ten-patient study, a 100% complete response rate was observed and no disease progression was documented through 18 months of median follow-up.”

In the study, patients were treated three times weekly with Triapine in combination with weekly cisplatin treatment and daily pelvic radiation therapy over five weeks. A phase two follow-up study is ongoing at the Ireland Cancer Center. UH Case Medical Center is the primary affiliate of Case Western Reserve University School of Medicine, a nationally recognized leader in medical research and education.

“Cervical cancer affects half a million women worldwide each year,” says Steven Waggoner, MD, Chief of Gynecologic Oncology at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. “We are pleased to have found a promising new treatment to help women fight this aggressive disease.”

Source :: NewsRx